Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes
June 27, 2011 (Issue: 1367)
Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a
third oral dipeptidyl peptidase-4 (DPP-4) enzyme
inhibitor, was recently approved by the FDA for treatment
of type 2 diabetes, either alone or in combination
with metformin, a sulfonylurea...more
1. DM Nathan et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193.
2. Sitagliptin (Januvia) for type 2 diabetes. Med Lett Drugs Ther 2007; 49:1.
3. Saxagliptin (Onglyza) for type 2 diabetes. Med Lett Drugs Ther 2009; 51:85.
4. S Del Prato et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258.
5. T Forst et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010; 27:1409.
6. MR Taskinen et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65.
7. R Gomis et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study. Diabetes Obes Metab 2011; 13:653.
8. AJ Lewin et al. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. European Association for the Study of Diabetes (EASD) 46th Annual Meeting; Stockholm, Sweden Sep 20-24, 2010; Poster No. 821-P.
9. DR Owens et al. Linagliptin improves glycemic control in type 2 diabetes patients inadequately controlled by metformin and sulfonylurea without weight gain and low risk of hypoglycemia. American Diabetes Association 70th Scientific Sessions, Orlando, Florida, June 25-29, 2010; Poster No. 548-P.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
